Glycolytic activity following anti-CD19 CAR-T cell infusion in non-Hodgkin lymphoma

Nicolas Vallet; Laurianne Drieu Larochelle; Maria-Joao Santiago-Ribeiro; Alban Villate; Martin Eloit; Arnaud Cirée; Laura Zaragoza; Virginie André; Marie Prat-Lepesant; Olivier Hérault; Flavie Arbion; Hélène Blasco; Emmanuel Gyan

doi:10.1111/eci.14342

Glycolytic activity following anti-CD19 CAR-T cell infusion in non-Hodgkin lymphoma

Eur J Clin Invest. 2024 Nov 1:e14342. doi: 10.1111/eci.14342. Online ahead of print.

Authors

Affiliations

¹ Hematology and Cell Therapy, University Hospital Tours, Tours, France.
² Inserm U1069 N2COx, University of Tours, Tours, France.
³ Department Imaging Nuclear Medicine, University Hospital Tours, Tours, France.
⁴ Department of Biological Immunology, University Hospital Tours, Tours, France.
⁵ Department of Pharmacy, University Hospital Tours, Tours, France.
⁶ Etablissement Français du Sang, Tours, France.
⁷ Department of Biological Hematology, University Hospital Tours, Tours, France.
⁸ Department of Pathology, University Hospital Tours, Tours, France.
⁹ Department of Biochemistry, University Hospital Tours, Tours, France.

PMID: 39487603
DOI: 10.1111/eci.14342

Abstract

Energy metabolism of chimeric antigen receptor-T cells (CAR-T) activation in humans remains unexplored. As a glycolytic activity surrogate, we investigated the dynamics of peripheral blood (PB) lactate in the first weeks post-CAR-T infusion. In 17 patients treated with CD28 harbording anti-CD19 CAR-T for relapsed/refractory non-Hodgkin lymphomas, PB lactate levels increased following CAR-T infusion. Elevated lactate levels correlated with longer CAR-T persistence and higher CD8+/CD4+ ratio. Peripheral blood lactate kinetics may reflect immune cells activation and be useful for bedside monitoring.

Keywords: CAR‐T cells; NHL; T cells; cell therapy; metabolism.